Form 13-F position report

AKOYA BIOSCIENCES INC

Reported by MORGAN STANLEY

AKYA CUSIP 00974H104 Manager CIK 0000895421

Reported 50,616 shares, up 10,404 (25.9%) from the prior quarter.

Reported value 46.7%; share count 25.9% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 50,616 Quarter-end amount reported
Reported value $650,000 Fair value at quarter end
Consecutive quarters held 5 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 435000
2022-03-31 443000
2022-06-30 650000
2022-09-30 532000
2022-12-31 413424
2023-03-31 244174
2023-06-30 275057
2023-09-30 155793
2023-12-31 423580
2024-03-31 299063
2024-06-30 253152
2024-09-30 463518
2024-12-31 297172
2025-03-31 158039
2025-06-30 107925
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for AKOYA BIOSCIENCES INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -83,019 (-100.0%) 0 $0 2025-11-14
Q2 2025 Reduced 83,019 -30,679 (-27.0%) < 0.01% $107,925 2025-08-15
Q1 2025 Reduced 113,698 -16,071 (-12.4%) < 0.01% $158,039 2025-05-15
Q4 2024 Reduced 129,769 -40,642 (-23.8%) < 0.01% $297,172 2025-02-14
Q3 2024 Added 170,411 +62,227 (57.5%) < 0.01% $463,518 2024-11-14
Q2 2024 Added 108,184 +44,418 (69.7%) < 0.01% $253,152 2024-08-14
Q1 2024 Reduced 63,766 -23,033 (-26.5%) < 0.01% $299,063 2024-05-15
Q4 2023 Added 86,799 +53,295 (159.1%) < 0.01% $423,580 2024-02-13
Q3 2023 Reduced 33,504 -3,716 (-10.0%) < 0.01% $155,793 2023-11-15
Q2 2023 Added 37,220 +7,370 (24.7%) < 0.01% $275,057 2023-08-14
Q1 2023 Reduced 29,850 -13,350 (-30.9%) < 0.01% $244,174 2023-05-15
Q4 2022 Reduced 43,200 -2,063 (-4.6%) < 0.01% $413,424 2023-02-14
Q3 2022 Reduced 45,263 -5,353 (-10.6%) < 0.01% $532,000 2022-11-14
Q2 2022 Added 50,616 +10,404 (25.9%) < 0.01% $650,000 2022-08-15
Q1 2022 Added 40,212 +11,751 (41.3%) < 0.01% $443,000 2022-05-13
Q4 2021 Reduced 28,461 -94,616 (-76.9%) < 0.01% $435,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

59 managers reported AKOYA BIOSCIENCES INC for Q2 2022.

Managers reporting AKOYA BIOSCIENCES INC in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Hudson Executive Capital LP Unchanged 2,447,558 0 3.99% $31,451,000 5 qtrs
Blue Water Life Science Advisors LP Added 2,104,785 +16,117 14.69% $27,046,000 3 qtrs
Board of Trustees of The Leland Stanford Junior University Reduced 1,572,861 -2 1.36% $20,211,000 5 qtrs
Polar Capital Holdings Plc Unchanged 1,315,470 0 0.1% $16,904,000 5 qtrs
BlackRock Inc Added 797,603 +20,602 < 0.01% $10,249,000 5 qtrs
VANGUARD GROUP INC Added 781,023 +80,200 < 0.01% $10,037,000 5 qtrs
MILLENNIUM MANAGEMENT LLC Added 718,063 +41,261 < 0.01% $9,227,000 5 qtrs
Altium Capital Management LP New 296,000 +296,000 1.52% $3,804,000 1 qtr
DEUTSCHE BANK AG Added 270,010 +261,897 < 0.01% $3,469,000 5 qtrs
FRED ALGER MANAGEMENT LLC Reduced 266,459 -5,358 0.02% $3,424,000 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
17,915
Shared
0
None
32,701

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.